{"id":"erydex-low-dose-dsp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Immunosuppression"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines dexamethasone with a drug-specific delivery system (DSP) technology to optimize pharmacokinetics and reduce systemic exposure. This approach aims to preserve anti-inflammatory and immunosuppressive efficacy while minimizing corticosteroid-related adverse effects associated with higher systemic doses.","oneSentence":"EryDex Low dose DSP is a dexamethasone-based formulation designed to deliver corticosteroid therapy at reduced systemic doses while maintaining local therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:31.388Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT02770807","phase":"PHASE3","title":"Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2017-03-02","conditions":"Nervous System Disease, Genetic Syndrome","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EryDex System end product"],"phase":"phase_3","status":"active","brandName":"EryDex Low dose DSP","genericName":"EryDex Low dose DSP","companyName":"Quince Therapeutics S.p.A.","companyId":"quince-therapeutics-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EryDex Low dose DSP is a small molecule that blocks the sodium channel protein type 9 subunit alpha. It is being studied in clinical trials for the treatment of nervous system diseases and genetic syndromes, including ataxia telangiectasia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}